IOVANCE BIOTHERAPEUTICS INC
NASDAQ: IOVA (Iovance Biotherapeutics, Inc.)
Last update: yesterday, 5:53AM2.45
-0.16 (-6.13%)
| Previous Close | 2.61 |
| Open | 2.65 |
| Volume | 9,584,198 |
| Avg. Volume (3M) | 14,463,640 |
| Market Cap | 972,571,520 |
| Price / Sales | 3.37 |
| Price / Book | 1.44 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -176.49% |
| Operating Margin (TTM) | -245.76% |
| Diluted EPS (TTM) | -1.22 |
| Quarterly Revenue Growth (YOY) | 6,798.50% |
| Total Debt/Equity (MRQ) | 7.00% |
| Current Ratio (MRQ) | 4.18 |
| Operating Cash Flow (TTM) | -334.39 M |
| Levered Free Cash Flow (TTM) | -184.76 M |
| Return on Assets (TTM) | -27.14% |
| Return on Equity (TTM) | -51.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Iovance Biotherapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.5 |
| Average | 1.88 |
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.37% |
| % Held by Institutions | 81.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mhr Fund Management Llc | 30 Sep 2025 | 28,967,103 |
| Invenomic Capital Management Lp | 30 Sep 2025 | 10,541,608 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (Chardan Capital, 593.88%) | Buy |
| Median | 10.00 (308.16%) | |
| Low | 9.00 (HC Wainwright & Co., 267.35%) | Buy |
| Average | 12.00 (389.80%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 17 Dec 2025 | 10.00 (308.16%) | Buy | 2.52 |
| 24 Nov 2025 | 9.00 (267.35%) | Buy | 2.50 | |
| Chardan Capital | 06 Nov 2025 | 17.00 (593.88%) | Buy | 2.31 |
| HC Wainwright & Co. | 29 Oct 2025 | 9.00 (267.35%) | Buy | 2.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2025 | Announcement | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 21 Nov 2025 | Announcement | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 06 Nov 2025 | Announcement | Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results |
| 03 Nov 2025 | Announcement | Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) |
| 23 Oct 2025 | Announcement | Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 |
| 17 Oct 2025 | Announcement | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 15 Oct 2025 | Announcement | Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |